Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage
biopharmaceutical company developing potential best-in-class oncology
therapies, today announced that the Japan Patent Office has granted
Patent No. 5270564 covering a series of novel isoquinolinamine
compounds, their pharmaceutical composition, and method for producing an
anti-tumor effect.
The patent includes inhibitors of the kinase activity of Aurora A, a
family of mitotic serine/threonine kinases. Aurora A kinase has been
shown to be over-expressed in many human cancer tumors including breast,
colon, leukemia, lung, head and neck, ovarian and prostate. In
preclinical studies, Rexahn's lead compound has shown anti-tumor
activity against human cancer cell lines that do not respond well to
paclitaxel, gemcitabine and cisplatin.
“The granting of this patent further strengthens Rexahn’s intellectual
property position in this exciting area. The preclinical activity of the
compound suggests its potential utility to treat multiple forms of
cancer including breast, colon, leukemia, lung, head and neck, ovarian
and prostate.” commented Peter D. Suzdak, CEO of Rexahn.
Rexahn has been awarded patents for the isoquinolinamine compounds in
the United States, Europe, Australia, China, Mexico, and now Japan.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company
dedicated to developing best-in-class therapeutics for the treatment of
cancer. Rexahn currently has three clinical stage oncology candidates,
Archexin®, RX-3117, and RX-5902 and a robust pipeline of
preclinical compounds to treat multiple types of cancer. Rexahn has also
developed proprietary drug discovery platform technologies in the areas
of nano-medicines, 3D-GOLD, and TIMES. For more information, please
visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal with
information that is not historical, these are forward-looking statements
under the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements about Rexahn's
plans, objectives, expectations and intentions with respect to future
operations and products and other statements identified by words such as
"will," "potential," "could," "can," "believe," "intends," "continue,"
"plans," "expects," "anticipates," "estimates," "may," other words of
similar meaning or the use of future dates. Forward-looking statements
by their nature address matters that are, to different degrees,
uncertain. Uncertainties and risks may cause Rexahn's actual results to
be materially different than those expressed in or implied by Rexahn's
forward-looking statements. For Rexahn, particular uncertainties and
risks include, among others, the difficulty of developing pharmaceutical
products, obtaining regulatory and other approvals and achieving market
acceptance; the marketing success of Rexahn's licensees or sublicensees;
the success of clinical testing; and Rexahn's need for and ability to
obtain additional financing. More detailed information on these and
additional factors that could affect Rexahn's actual results are
described in Rexahn's filings with the Securities and Exchange
Commission, including its most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q. All forward-looking
statements in this news release speak only as of the date of this news
release. Rexahn undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Copyright Business Wire 2013